Let’s be clear: a well-designed and well-conducted Phase III drug trial that has very few or no missing data and robust statistics but does not demonstrate positive efficacy and safety for a potential new therapeutic agent is not a “failed trial.”  It’s a good trial with a negative outcome. On the other hand, a poorly…